MX2022006000A - Composicion de cultivo de linfocitos t reguladores y su uso. - Google Patents
Composicion de cultivo de linfocitos t reguladores y su uso.Info
- Publication number
- MX2022006000A MX2022006000A MX2022006000A MX2022006000A MX2022006000A MX 2022006000 A MX2022006000 A MX 2022006000A MX 2022006000 A MX2022006000 A MX 2022006000A MX 2022006000 A MX2022006000 A MX 2022006000A MX 2022006000 A MX2022006000 A MX 2022006000A
- Authority
- MX
- Mexico
- Prior art keywords
- regulatory
- cells
- lymphocytes
- culture
- effectively
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 239000006143 cell culture medium Substances 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 238000012136 culture method Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000013636 protein dimer Substances 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un método para cultivar con efectividad linfocitos T reguladores y, específicamente, un dímero de proteína de fusión que contiene IL-2 o una variante de esta y CD80 o un fragmento de esta que puede hacer proliferar con efectividad linfocitos T CD4+, CD25+ y CD127-. Además, la proteína de fusión puede hacer que proliferen con efectividad linfocitos T reguladores tales como linfocitos T CD4+, CD25+ y CD127- en combinación con un medio de cultivo celular específico. Adicionalmente, de acuerdo con el método, se confirmó que la viabilidad de los linfocitos T reguladores aumentó significativamente en comparación con un método de cultivo que usaba IL-2 usada convencionalmente, y la cantidad de linfocitos T reguladores Foxp3+ obtenidos aumentó significativamente. Por tanto, este método de proliferación puede usarse en el campo de la terapia celular mediante el uso de linfocitos T reguladores.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190149779 | 2019-11-20 | ||
| KR20200033229 | 2020-03-18 | ||
| PCT/KR2020/016382 WO2021101273A2 (ko) | 2019-11-20 | 2020-11-19 | 조절 t 세포 배양용 조성물 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006000A true MX2022006000A (es) | 2022-06-17 |
Family
ID=75980980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006000A MX2022006000A (es) | 2019-11-20 | 2020-11-19 | Composicion de cultivo de linfocitos t reguladores y su uso. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11702633B2 (es) |
| EP (1) | EP4063490A4 (es) |
| JP (1) | JP7425195B2 (es) |
| KR (1) | KR102325857B1 (es) |
| CN (2) | CN114901807B (es) |
| AU (1) | AU2020387479B2 (es) |
| BR (1) | BR112022008129A2 (es) |
| CA (1) | CA3152351A1 (es) |
| IL (1) | IL291909A (es) |
| MX (1) | MX2022006000A (es) |
| SA (1) | SA522432641B1 (es) |
| TW (1) | TWI812901B (es) |
| WO (1) | WO2021101273A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114829585B (zh) * | 2019-11-20 | 2024-08-23 | 吉爱希公司 | 用于培养t细胞的组合物及使用其来培养t细胞的方法 |
| CN114867847A (zh) * | 2019-11-20 | 2022-08-05 | 吉爱希公司 | 用于培养自然杀手细胞的组合物及使用其来生产自然杀手细胞的方法 |
| KR102733064B1 (ko) | 2022-10-17 | 2024-11-21 | 주식회사 이뮤니스바이오 | Treg 세포 분화 및 활성화를 이용한 IBD치료용 약제학적 조성물 |
| KR20240177180A (ko) * | 2023-06-19 | 2024-12-27 | (주)엑셀세라퓨틱스 | T 세포 배양용 배지 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229109A (en) * | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| CA2633161A1 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding t regulatory cells |
| CN101378783A (zh) * | 2005-12-08 | 2009-03-04 | 路易斯维尔大学研究基金会有限公司 | 用于扩增t调节细胞的方法和组合物 |
| IL269687B (en) | 2011-02-10 | 2022-08-01 | Roche Glycart Ag | Interleukin-2 polypeptides |
| PE20181300A1 (es) * | 2015-11-02 | 2018-08-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer |
| WO2017220988A1 (en) * | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
| LT3606946T (lt) * | 2017-04-03 | 2022-10-25 | F. Hoffmann-La Roche Ag | Anti-pd-1 antikūno imunokonjugatai su mutantiniu il-2 arba su il-15 |
| CN110392392B (zh) | 2018-04-16 | 2021-07-09 | 华为技术有限公司 | 通信方法、通信装置及可读存储介质 |
-
2020
- 2020-11-19 EP EP20890419.3A patent/EP4063490A4/en active Pending
- 2020-11-19 CN CN202080078640.8A patent/CN114901807B/zh active Active
- 2020-11-19 MX MX2022006000A patent/MX2022006000A/es unknown
- 2020-11-19 IL IL291909A patent/IL291909A/en unknown
- 2020-11-19 CN CN202310807404.0A patent/CN117004564A/zh not_active Withdrawn
- 2020-11-19 BR BR112022008129A patent/BR112022008129A2/pt unknown
- 2020-11-19 JP JP2022529596A patent/JP7425195B2/ja active Active
- 2020-11-19 KR KR1020200155385A patent/KR102325857B1/ko active Active
- 2020-11-19 WO PCT/KR2020/016382 patent/WO2021101273A2/ko not_active Ceased
- 2020-11-19 CA CA3152351A patent/CA3152351A1/en active Pending
- 2020-11-19 AU AU2020387479A patent/AU2020387479B2/en active Active
- 2020-11-20 TW TW109140867A patent/TWI812901B/zh active
-
2022
- 2022-05-12 US US17/743,181 patent/US11702633B2/en active Active
- 2022-05-18 SA SA522432641A patent/SA522432641B1/ar unknown
-
2023
- 2023-05-15 US US18/317,199 patent/US20230407253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4063490A4 (en) | 2023-08-23 |
| CA3152351A1 (en) | 2021-05-27 |
| EP4063490A2 (en) | 2022-09-28 |
| IL291909A (en) | 2022-06-01 |
| US20220290102A1 (en) | 2022-09-15 |
| CN117004564A (zh) | 2023-11-07 |
| US11702633B2 (en) | 2023-07-18 |
| JP2022547352A (ja) | 2022-11-11 |
| CN114901807B (zh) | 2023-07-11 |
| JP7425195B2 (ja) | 2024-01-30 |
| KR20210061950A (ko) | 2021-05-28 |
| TWI812901B (zh) | 2023-08-21 |
| BR112022008129A2 (pt) | 2022-08-23 |
| AU2020387479A1 (en) | 2022-05-26 |
| NZ787703A (en) | 2025-05-30 |
| SA522432641B1 (ar) | 2024-10-24 |
| WO2021101273A3 (ko) | 2021-07-15 |
| US20230407253A1 (en) | 2023-12-21 |
| TW202132562A (zh) | 2021-09-01 |
| KR102325857B9 (ko) | 2021-12-07 |
| KR102325857B1 (ko) | 2021-11-12 |
| AU2020387479B2 (en) | 2024-06-06 |
| CN114901807A (zh) | 2022-08-12 |
| WO2021101273A2 (ko) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006000A (es) | Composicion de cultivo de linfocitos t reguladores y su uso. | |
| MX2022001776A (es) | Terapias de combinacion de inmuno oncologia con conjugados de il-2. | |
| CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
| MX2020004568A (es) | Combinación de una terapia celular y un inhibidor de gamma secretasa. | |
| MX2022012196A (es) | Metodos para cultivar celulas y kits y aparatos para ello. | |
| EP4286511A3 (en) | Method to treat cancer with engineered t-cells | |
| BR112016028512A2 (pt) | métodos de cultivo por perfusão e seu uso | |
| BR112015030946A8 (pt) | composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa | |
| MX2016016076A (es) | Composiciones de celulas t mejoradas. | |
| AU2017261380A1 (en) | Genetically engineered cells and methods of making the same | |
| MX2024012982A (es) | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t | |
| AR094375A1 (es) | Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular | |
| MX2016013963A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX395154B (es) | Métodos, kits, agentes y aparatos para transducción. | |
| MY171710A (en) | Culture medium composition, and method for culturing cell or tissue using said composition | |
| BR112013002811A8 (pt) | meios básicos simplificados para cultura celular pluripotente de humano | |
| SG10201809452RA (en) | Cell culture compositions with antioxidants and methods for polypeptide production | |
| CL2017001903A1 (es) | Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante | |
| MX2020003605A (es) | Manipulación del metabolismo de triptamina. | |
| CR20160307A (es) | Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas | |
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
| MX2020004939A (es) | Fabricacion de composiciones de celulas islote y metodos de uso de las mismas. | |
| CL2017000891A1 (es) | Métodos de cultivo semicontinuo | |
| WO2018009528A8 (en) | Combination cancer immunotherapies with arginine depletion agents | |
| CL2019003595A1 (es) | Bacterias probióticas preacondicionadas en un medio que contiene gos y uso de estas. |